Search

Boehringer Ingelheim Launches Observational Study on Management of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) with Pradaxa® (dabigatran etexilate mesylate)

Our Curiosity Never Stops | Boehringer Ingelheim US

Hear from Dr. Cornelia Dorner-Ciossek on how brain research informs treatment methods for patients suffering with mental illnesses.

The Importance of Drug Discovery | R&D | Boehringer Ingelheim US

Research & Development

Boehringer Ingelheim Acquires Northern Biologics’ Preclinical Cancer Antibody Pipeline, Expanding Immuno-oncology Portfolio

Boehringer Ingelheim Collaborates with Proxygen to Explore Molecular Glue Degraders - a Novel Approach to Fight Cancer

About our Innovation Prize

Established in 2015 and jointly sponsored by BI and the BI Venture Fund, the prize allows recipients to focus on development of breakthrough medicines.

Sophia Malki: A Woman on the Rise

Discovery Research Global Post-Doc Program

Evolving the Unwearable Collection

Boehringer Ingelheim will partner with the Fashion Institute of Technology in New York to introduce a fifth design as part of The Unwearable Collection™

New Swine Vaccine Combination Released | Boehringer Ingelheim US

Click here to read more on the introduction of another new swine vaccination combination from Boehringer Ingelheim, protecting pigs from common viruses.

Our partners Bioveta

Our partner Bioveta shares insights about the longstanding collaboration with Boehringer Ingelheim and the evolution of the partnership

Jardiance shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40% regardless of chronic kidney disease status

Sant Cugat del Vallès (Barcelona)

Boehringer Ingelheim settled in Spain in 1952. For almost 70 years, t

Ingelheim

The company headquarters of Boehringer Ingelheim are located in Ingelheim, Germany.

Talking drug discovery with our U.S. research site head, Carine Boustany

Learn about the challenges and victories of developing new medicine for conditions, like generalized pustular psoriasis (GPP) flares in adults.

Medical Affairs & Scientific Comms. | Boehringer Ingelheim US

Boehringer Ingelheim is proud to offer a 2-year, rotation-based, Fellowship program within Medical Affairs & Scientific Communications.

Boehringer Ingelheim Statement: Favorable Ruling on Humira® Patent Challenge from U.S. Patent and Trademark Office

Vienna

Vienna is a cornerstone within the company’s global R&D network, with a special focus on cancer research. On top of that, it is also a hub for biopharmaceutical development and production.

Boehringer Ingelheim, Fashion Institute of Technology’s DTech Lab introduce fifth piece to award-winning design collection that raises awareness of rare disease

US FDA approves the Cyltezo® Pen, a new autoinjector option, ahead of July 1 commercial launch

Employees compassionately help local communities with country-wide food drive

Coming together to bring food to people in need

Boehringer Ingelheim Partners with Thoeris to Investigate a Novel Approach to Treat Urea Cycle Disorders

Clinical Trials

Boehringer Ingelheim is committed to advancing the discovery of new medicines through clinical trials.

Biosimilar Cyltezo® demonstrates clinical equivalence to Humira® in patients with moderate-to-severe plaque psoriasis

Boehringer Ingelheim Announces Agreement to Study Real-World Use of Oral Anticoagulants

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers